Format

Send to

Choose Destination
Transplantation. 2017 Jun;101(6):1222-1227. doi: 10.1097/TP.0000000000001330.

32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody.

Author information

1
1 Division of Transplantation Surgery, Mayo Clinic, Rochester, MN. 2 Division of Transfusion Medicine, Mayo Clinic, Rochester, MN. 3 Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN. 4 Division of Health Sciences Research, Mayo Clinic, Rochester, MN. 5 Division of Transplantation Surgery and von Liebig Transplant Center, Mayo Clinic, Rochester, MN.

Abstract

BACKGROUND:

We previously showed that bortezomib (BTZ) partially depletes plasma cells, yet has limited efficacy for desensitization in kidney transplant candidates when up to 16 doses is given.

METHODS:

This study aimed to determine the safety and efficacy of 32 doses of BTZ (1.3 mg/m of body surface area) in 10 highly sensitized kidney transplant candidates with alloantibodies against their intended living donor.

RESULTS:

Dose reduction was needed in 2 patients and 2 others completely discontinued therapy for adverse events. Anti-HLA antibodies mean fluorescence intensity (MFI) values were stable prior to BTZ (P = 0.96) but decreased after therapy (mean decrease of 1916 [SE, 425] MFI, P < 0.01). No patient developed a negative crossmatch against their original intended donor, and the calculated panel-reactive antibodies based on MFI of 2000, 4000, and 8000 was unchanged in all patients.

CONCLUSIONS:

These data suggest that 32 doses of BTZ monotherapy was not well tolerated and resulted in only a modest reduction in anti-HLA antibodies.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00722722.

PMID:
27379560
PMCID:
PMC4935916
DOI:
10.1097/TP.0000000000001330
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center